Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOBLET study of pelareorep- and atezolizumab-based combinations in advanced gastrointestinal cancers
2024-515936-62-00Phase 2Authorised
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and pelareorep in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), anal squamous cell carcinoma (SCCA) and 1 more (6 cohorts), sponsored by Oncolytics Biotech Inc. Primary endpoints: Objective response rate and Safety and tolerability in cohort 5. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumabpelareorep
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)anal squamous cell carcinoma (SCCA)gastrointestinal cancer
Beyond the preview
Go deeper on 2024-515936-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515936-62-00.